Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.60 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.60 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576717 | 0.89 | LPAR3 (0.64) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL2523093 | 0.84 | LPAR3 (0.43) | LPAR3LPAR2LPAR1ALDH1A1CYP3A4 | |
| SCHEMBL1514200 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL27555558 | 0.83 | LPAR3 (0.58) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL1574125 | 0.83 | LPAR3 (0.71) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL15729175 | 0.82 | SAT1 (0.52) | LPAR3LPAR2LPAR1ALDH1A1CYP3A4 | |
| SCHEMBL12254989 | 0.82 | SAT1 (0.52) | LPAR3LPAR2LPAR1ALDH1A1CYP3A4 | |
| SCHEMBL27283647 | 0.81 | LPAR3 (0.50) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| Ammonia Solution, Strong SCHEMBL27732597 | 0.81 | LPAR3 (0.50) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL6033633 | 0.80 | LPAR3 (0.76) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396351-A1 | COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| WO-2023034868-A1 | COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | claimed |
| EP-2337805-B2 | POLYMERIZABLE LIQUID COMPOSITION AND PROCESS FOR THE PRODUCTION OF ORGANIC GLASS STARTING FROM POLYMERIZABLE LIQUID COMPOSITIONS OF THE POLYURETHANE TYPE | MITSUI CHEMICALS INC (JP) | 2025-06-18 | — | — | EP | disclosed |
| CN-119654413-A | ITFG1 inhibitory nucleic acids | 莱尔纳生物制药私人有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119452086-A | GAPMER antisense oligonucleotides with modified backbone chemistry | 奎里斯公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025031485-A1 | DSRNA MOLECULE INHIBITING HBV GENE EXPRESSION AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2025-02-13 | — | — | WO | disclosed |
| EP-4396351-A1 | COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3129353-B1 | METHOD FOR MANUFACTURING XYLYLENE DIISOCYANATES IN THE GASEOUS PHASE | COVESTRO DEUTSCHLAND AG (DE) | 2024-02-28 | — | — | EP | disclosed |
| CN-116802294-A | Therapeutic agent for treating neurodegenerative disease | UCL商业有限公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023106258-A1 | POLYMERIZABLE COMPOSITION FOR MANUFACTURING MOLDED ARTICLE, MOLDED ARTICLE AND MANUFACTURING METHOD THEREOF | MITSUI CHEMICALS, INC. (JP) | 2023-06-15 | — | — | WO | disclosed |
| WO-2015155367-A1 | COMPOSITION CONTAINING AROMATIC NITRILES FOR THE PRODUCTION OF TRANSPARENT POLYTHIOURETHANE BODIES | BAYER MATERIALSCIENCE AG (DE) | 2015-10-15 | — | — | WO | disclosed |
| EP-2337805-B1 | POLYMERIZABLE LIQUID COMPOSITION AND PROCESS FOR THE PRODUCTION OF ORGANIC GLASS STARTING FROM POLYMERIZABLE LIQUID COMPOSITIONS OF THE POLYURETHANE TYPE | ACOMON AG (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-8829147-B2 | Polymerizable liquid composition and process for the production of organic glass starting from polymerizable liquid compositions of the polyurethane type | ACOMON AG (CH) | 2014-09-09 | — | — | US | disclosed |
| EP-2571914-A1 | A POLYMERIZATION CATALYST FOR POLYTHIOURETHANES, POLYMERIZABLE LIQUID COMPOSITION AND PROCESS FOR THE PRODUCTION OF ORGANIC POLYTHIOURETHANE GLASS WITH A HIGH REFRACTIVE INDEX | Mitsui Chemicals, Inc. (JP) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011144995-A1 | A POLYMERIZATION CATALYST FOR POLYTHIOURETHANES, POLYMERIZABLE LIQUID COMPOSITION AND PROCESS FOR THE PRODUCTION OF ORGANIC POLYTHIOURETHANE GLASS WITH A HIGH REFRACTIVE INDEX | ACOMON AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20110251301-A1 | POLYMERIZABLE LIQUID COMPOSITION AND PROCESS FOR THE PRODUCTION OF ORGANIC GLASS STARTING FROM POLYMERIZABLE LIQUID COMPOSITIONS OF THE POLYURETHANE TYPE | ACOMON AG (CH) | 2011-10-13 | — | — | US | disclosed |
| EP-2337805-A1 | POLYMERIZABLE LIQUID COMPOSITION AND PROCESS FOR THE PRODUCTION OF ORGANIC GLASS STARTING FROM POLYMERIZABLE LIQUID COMPOSITIONS OF THE POLYURETHANE TYPE | ACOMON AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010043392-A1 | POLYMERIZABLE LIQUID COMPOSITION AND PROCESS FOR THE PRODUCTION OF ORGANIC GLASS STARTING FROM POLYMERIZABLE LIQUID COMPOSITIONS OF THE POLYURETHANE TYPE | ACOMON AG (CH) | 2010-04-22 | — | — | WO | disclosed |
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | CCNI, MKI67, TP53 | LPAR3 2807/4885LPAR2 4186/4885LPAR1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.